Disease Info Card

Neuroleptic Malignant Syndrome

Information about Neuroleptic Malignant Syndrome: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Neuroleptic Malignant Syndrome

Most recent studies have shown that Neuroleptic Malignant Syndrome shares some biological mechanisms with agitation, basal-ganglia-diseases, bipolar-disorder, catatonia, depressive-disorder, dyskinetic-syndrome, lethal-catatonia, malignant-hyperpyrexia-due-to-anesthesia, malignant-paraganglionic-neoplasm, mental-disorders, movement-disorders, muscle-rigidity, neonatal-maladjustment-syndrome, parkinson-disease, psychotic-disorders, rhabdomyolysis, schizophrenia, secondary-parkinson-disease, serotonin-syndrome, substance-withdrawal-syndrome.

Among the many pathways, these few ones have gauged particular interests from scientists studying Neuroleptic Malignant Syndrome, and have been seen in publications frequently: Blood Coagulation, Cardiac Conduction, Cell Death, Coagulation, Cognition, Cytolysis, Diuresis, Heat Dissipation, Heat Generation, Hormone Secretion, Hypersensitivity, Menstruation, Muscle Contraction, Oxidative Phosphorylation, Pathogenesis, Reflex, Secretion, Transport, Vasoconstriction

Quite a number of genes have been found to play important roles in Neuroleptic Malignant Syndrome, such as ATP6V0A1, AVP, BCHE, CHKA, CHKB, COMT, CSF2, CYP2D6, DIO2, DRD2, HTR1A, LAMC2, MB, NHLRC1, NMS, PIK3C2A, RFC1, RFC2, SLC25A10. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.